Multiple Sclerosis

We recommend

Balance and Rehabilitation –⁠ Firm on the Ground Even with Multiple Sclerosis

1. 11. 2023 Source: Multiple Sclerosis

A large portion of patients with multiple sclerosis (MS) suffer from balance disorders. What are the options for non-pharmacological therapy for these issues according to the latest studies?

Neutropenia with Thrombocytopenia after Alemtuzumab? −⁠ Case Report

Early neutropenia with thrombocytopenia is not a common side effect of alemtuzumab. However, the…

1. 11. 2023 Source: Multiple Sclerosis

MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information

How to offer a helping hand to patients amidst the flood of information and why is communication…

15. 8. 2023 Source: Multiple Sclerosis

Articles on this topic

48 Tablets of Teriflunomide? Nothing Should Be Overdone! −⁠ Case Study

A case study published in the Journal of Clinical Pharmacy and Therapeutics describes an…

15. 8. 2023 Source: Multiple Sclerosis

Vaccination and ALEmtuzumab: ALE when?

When, why and against what should patients with multiple sclerosis treated with alemtuzumab be…

5. 6. 2023 Source: Multiple Sclerosis

Traveling with MS –⁠ Is Vaccination a Limitation?

What about the need for vaccination when traveling abroad? Which vaccines should you be…

5. 6. 2023 Source: Multiple Sclerosis

Adherence to Treatment of Multiple Sclerosis: How to Enhance It and What Interesting Insights Emerged from Current Research?

Therapeutic options for patients with multiple sclerosis (MS) utilizing disease-modifying drugs...

24. 4. 2023 Source: Multiple Sclerosis

Teriflunomide in the Treatment of RRMS: The Best Working Drug Is the One That the Patient Actually Takes

Teriflunomide is an oral disease-modifying drug (DMD) used in the therapy of relapsing-remitting...

24. 4. 2023 Source: Multiple Sclerosis

Teriflunomide "under the microscope" or what it's like to live with MS in the North

The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect…

12. 1. 2023 Source: Multiple Sclerosis

Smouldering Multiple Sclerosis: How Can MRI Help in Its Identification?

With the changing understanding of the etiopathogenesis of multiple sclerosis, several new…

4. 1. 2023 Source: Multiple Sclerosis

Teriflunomide vs. Dimethyl Fumarate: Does Their Classification into Different Treatment Lines Have Merit?

Teriflunomide is one of the first-choice medications in the treatment of multiple sclerosis…

4. 1. 2023 Source: Multiple Sclerosis

Tailored Treatment. Who is Teriflunomide Suitable For?

The authors of the recently published study cited below not only focused on the safety and…

3. 11. 2022 Source: Multiple Sclerosis

The Future of Multiple Sclerosis –⁠ Time for a Change in Classification?

What are the latest findings on the etiopathogenesis of multiple sclerosis? Are they reflected…

3. 11. 2022 Source: Multiple Sclerosis

Cognitive changes in MS –⁠ what can teriflunomide do?

In Phase III clinical trials, teriflunomide demonstrated its ability to slow down brain tissue…

10. 10. 2022 Source: Multiple Sclerosis

To Vaccinate or Not to Vaccinate? That’s the Question for MS and COVID-19

What is the response of patients with multiple sclerosis (MS) to vaccination against COVID-19…

10. 10. 2022 Source: Multiple Sclerosis

MS in Children –⁠ An Overlooked Sister of Adult Diseases?

Multiple sclerosis is not just an adult disease. How common is it in children and how have…

6. 6. 2022 Source: Multiple Sclerosis

Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children –⁠ Results of the TERIKIDS Study

Therapeutic options for multiple sclerosis in the pediatric population are limited. However,…

1. 6. 2022 Source: Multiple Sclerosis

Focused on MS: Statistics Are Boring, But They Have Valuable Data!

What is the prevalence of multiple sclerosis? Has the proportion of patients treated with…

23. 5. 2022 Source: Multiple Sclerosis

1 2 3